Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation that ultimately leads to kidney failure in most patients. Approximately 10% of patients who receive kidney replacement therapy suffer from ADPKD. To date, a vasopressin V2 receptor antagonist (V2RA) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bais, Thomas, Gansevoort, Ron T., Meijer, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329410/
https://www.ncbi.nlm.nih.gov/pubmed/35852784
http://dx.doi.org/10.1007/s40265-022-01745-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329410/
https://www.ncbi.nlm.nih.gov/pubmed/35852784
http://dx.doi.org/10.1007/s40265-022-01745-9

Ejemplares similares